Ignite Creation Date:
2024-05-06 @ 1:55 AM
Last Modification Date:
2024-10-26 @ 11:11 AM
Study NCT ID:
NCT01930474
Status:
UNKNOWN
Last Update Posted:
2013-12-05
First Post:
2013-08-21
Brief Title:
Analysis of Plasma Tumor DNA in Lung Cancer Patients
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Analysis of Mechanism of Resistance to Chemotherapy by Sequencing of Plasma DNA
Status:
UNKNOWN
Status Verified Date:
2013-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The presence of genetic alterations in the tyrosine kinase domain of the oncogene eg EGFR and ALK is associated with the clinical response to tyrosine kinase inhibitors TKIs in patients with non-small cell lung cancers Therefore the detection of altered genetic alterations is useful for predicting the treatment response for TKIs in non-small cell lung cancer patients However good quality tumor tissues are available only in 50 of patients with inoperable lung cancer for mutation analysis In this study the investigators will detect and quantify the genetic alterations in plasma the investigators will investigate if the serial measurement of cancer-derived genetic alterations in plasma can provide a means for monitoring disease progression as well as treatment response In addition the investigators will analysis the resistant mechanism of TKIs and chemotherapy with plasma tumor DNA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B-1307210-005 | OTHER | SeoulNUH | None |